Cabrellis Pharmaceuticals
San Diego
About Cabrellis Pharmaceuticals
Cabrellis Pharmaceuticals Corporation, a specialty pharmaceutical company developing therapies for the treatment of cancer. Cabrellis plans to initiate three separate clinical trials in small cell lung cancer (SCLC) in 2006. The first trial, designed to assess the safety and efficacy of Calsed(TM) in reference to topotecan in the second-line treatment of patients with SCLC who previously responded to platinum-based chemotherapy, is currently underway at multiple clinical trial sites in the United States.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $27.5M
- Funding stage: M&A
- Last round: Series A (Aug 2006)
- Website: cabrellis.com
- Phone: (858)404-1777
Industries & Categories
Health Care, Health Diagnostics, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/cabrellis-pharmaceuticals-3273398 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.